Xenimmune
Cambridge, US · 1 known investors
Find your way into Xenimmune
673 people in our graph share verified history with the Xenimmune team — schools, employers, funds. One of them is your warm intro.
Adam Valkinunlockedknows Richard Lim · together at Harvard University (overlapped)
×7knows the team · via Harvard Business School
×4knows the team · via Harvard University
XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.
Founders & leadership
RJ
Richard J. LiminChief Executive OfficerRichard J. Lim is CEO of XenImmune, an immuno-oncology company. With over 30 years in life sciences, he co-founded Cure Ventures, a venture capital firm focused on drug discovery and development companies, alongside Lou Tartaglia and Dave Fallace.
Investors · 1
Frequently asked questions
- What does Xenimmune do?
- XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.
- Who are Xenimmune's investors?
- Xenimmune's investors include Cure Ventures.
- Where is Xenimmune headquartered?
- Xenimmune is headquartered in Cambridge, US.